Drug Profile

Erdafitinib - Janssen Pharmaceutica

Alternative Names: BALVERSA; Barbasa; Barbaza; G-024; JNJ-42756493; JNJ-493; TAR-210

Latest Information Update: 28 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astex Therapeutics; Newcastle University
Developer Genentech; Janssen Pharmaceutica; Janssen Research & Development; Multiple Myeloma Research Consortium; National Cancer Institute (USA); University Health Network of Toronto; University of Washington; Vanderbilt-Ingram Cancer Center
Class Antineoplastics; Diamines; Pyrazoles; Quinoxalines; Small molecules
Mechanism of Action Fibroblast growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Urogenital cancer
Phase III Bladder cancer
Phase II Cholangiocarcinoma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours
Phase I/II Liver cancer
No development reported Breast cancer; Lymphoma

28 Apr 2026 No recent reports of development identified for phase-I development in Bladder-cancer in Japan (Intravesicular)
13 Mar 2026 Updated efficacy and adverse event data from the phase I/II MoonRISe-2 trial in Bladder cancer released by Johnson & Johnson
28 Feb 2026 Janssen Research & Development completes the phase II RAGNAR trial in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable, In adolescents, In children) in France, Spain, USA, Japan, Argentina, Australia, Belgium, Brazil, China, Germany, Italy, South Korea, Poland, Taiwan, United Kingdom (PO) (NCT04083976)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com